Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Marksans Pharma Limited, often known simply as Marksans Pharma, is a prominent pharmaceutical preparation manufacturing company headquartered in India (IN). Established in 1992, the company has grown into a global pharmaceutical force, operating across key markets including the UK, USA, and Australia.
Specialising in the development, manufacturing, and marketing of a diverse portfolio of prescription and over-the-counter (OTC) medications, Marksans Pharma focuses on delivering high-quality, affordable healthcare solutions. Their comprehensive product range spans various therapeutic areas, catering to a wide spectrum of patient needs. Marksans Pharma's commitment to robust research and development, coupled with stringent quality control, underpins its success in the competitive pharmaceutical landscape.
-4 vs industry average
Marksans Pharma’s score of 38 is lower than 49% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Marksans Pharma reported total carbon emissions of approximately 21,868,979 kg CO2e, comprising 19,912,486 kg CO2e from Scope 1 and 1,530,493 kg CO2e from Scope 2 emissions. Notably, there were no reported Scope 3 emissions for this year.
The previous year, 2024, saw a total of approximately 23,130,250 kg CO2e, with all emissions attributed to Scope 1, as no Scope 2 or Scope 3 data was disclosed. In 2023, the company reported approximately 22,110,220 kg CO2e, again solely from Scope 1 emissions.
Marksans Pharma has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of Scope 3 emissions data suggests that the company may need to enhance its reporting practices to align with industry standards.
Overall, while Marksans Pharma has made strides in tracking its emissions, the lack of comprehensive data and reduction initiatives highlights opportunities for improvement in its climate strategy.
No climate goals have been disclosed for Marksans Pharma yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more